Published in Cancer on May 01, 2009
Presentation, treatment, and outcomes of dural metastases in men with metastatic castrate-resistant prostate cancer: a case series. J Palliat Med (2010) 1.18
Metastatic skull tumors: MRI features and a new conventional classification. J Neurooncol (2010) 1.02
Dural metastases from prostate cancer mimicking acute sub-dural hematoma. Emerg Radiol (2012) 0.93
Dural metastases in advanced prostate cancer: a case report and review of the literature. Curr Urol (2014) 0.92
Dural-based metastatic carcinomas mimicking primary CNS neoplasia: report of 7 cases emphasizing the role of timely surgery and accurate pathologic evaluation. Int J Clin Exp Pathol (2011) 0.88
Subdural Metastasis of Prostate Cancer. J Neurol Surg Rep (2015) 0.80
Leptomeningeal carcinomatosis associated with papillary renal cell carcinoma. Ecancermedicalscience (2014) 0.75
Metastatic Breast Lesion to the Falx Detected with PET-CT. Nucl Med Mol Imaging (2012) 0.75
Metastatic site-specific polarization of macrophages in intracranial breast cancer metastases. Oncotarget (2016) 0.75
Metastatic prostate mass to the intradural foramen magnum region: a case report. J Neurol Surg Rep (2012) 0.75
Prostate carcinoma mimicking a sphenoid wing meningioma. Int J Surg Case Rep (2015) 0.75
Dural metastasis of nasopharyngeal carcinoma: rare, but worth considering. Singapore Med J (2014) 0.75
Intraparenchymal hemorrhage from dural metastasis of breast cancer mimicking meningioma. Neuroradiol J (2016) 0.75
Widespread subdural metastasis from breast cancer progressing rapidly with cerebral herniation: A case report. Mol Clin Oncol (2017) 0.75
Primary intracranial dural-based Ewing sarcoma/peripheral primitive neuroectodermal tumor mimicking a meningioma: A rare tumor with review of literature. Asian J Neurosurg (2017) 0.75
Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol (2009) 14.15
Scale to predict survival after surgery for recurrent glioblastoma multiforme. J Clin Oncol (2010) 2.67
Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol (2007) 2.62
Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01. Clin Cancer Res (2005) 2.46
Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res (2006) 2.44
Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology (2004) 2.41
Patterns of care in elderly glioblastoma patients. Ann Neurol (2008) 2.17
Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys (2009) 2.07
Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol (2011) 1.95
The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma. Cancer (2004) 1.81
Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol (2006) 1.74
High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib. Cancer (2005) 1.69
A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neuro Oncol (2009) 1.66
International study on low-grade primary central nervous system lymphoma. Ann Neurol (2006) 1.59
Advancing the treatment of malignant glioma: act local, think global. Cancer Invest (2004) 1.59
Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma. J Clin Oncol (2009) 1.58
Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. J Clin Oncol (2013) 1.54
International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors. Neuro Oncol (2011) 1.53
Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02). Neuro Oncol (2010) 1.46
Methotrexate area under the curve as a prognostic factor in primary central nervous system lymphoma treated with immunochemoradiotherapy. Leuk Lymphoma (2011) 1.45
Primary CNS lymphoma of T-cell origin: a descriptive analysis from the international primary CNS lymphoma collaborative group. J Clin Oncol (2005) 1.44
Salvage whole brain radiotherapy for recurrent or refractory primary CNS lymphoma. Neurology (2007) 1.43
Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study. J Neurooncol (2012) 1.42
Maintenance therapy for central nervous system lymphoma with rituximab. Leuk Lymphoma (2009) 1.39
Immediate titanium mesh cranioplasty for treatment of postcraniotomy infections. World Neurosurg (2011) 1.39
Summary statement on primary central nervous system lymphomas from the Eighth International Conference on Malignant Lymphoma, Lugano, Switzerland, June 12 to 15, 2002. J Clin Oncol (2003) 1.39
Capecitabine therapy of central nervous system metastases from breast cancer. J Neurooncol (2007) 1.37
Therapeutic challenges in primary CNS lymphoma. Lancet Neurol (2009) 1.36
Prospective cognitive follow-up in primary CNS lymphoma patients treated with chemotherapy and reduced-dose radiotherapy. J Neurooncol (2008) 1.36
Glioblastoma in the elderly: the Memorial Sloan-Kettering Cancer Center Experience (1997-2007). Cancer (2009) 1.35
Delayed neurotoxicity in primary central nervous system lymphoma. Arch Neurol (2005) 1.35
A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM). J Neurooncol (2008) 1.31
Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08). Neuro Oncol (2009) 1.30
Antiangiogenic agents in the treatment of recurrent or newly diagnosed glioblastoma: analysis of single-agent and combined modality approaches. Radiat Oncol (2011) 1.29
Cognitive functions in primary CNS lymphoma after single or combined modality regimens. Neuro Oncol (2011) 1.25
Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. J Neurooncol (2009) 1.21
A phase II study of extended low-dose temozolomide in recurrent malignant gliomas. Neuro Oncol (2002) 1.20
Primary dural lymphomas: a review. Neurosurg Focus (2006) 1.19
Response assessment criteria for glioblastoma: practical adaptation and implementation in clinical trials of antiangiogenic therapy. Curr Neurol Neurosci Rep (2013) 1.16
Trends in survival from primary central nervous system lymphoma, 1975-1999: a population-based analysis. Cancer (2005) 1.15
Treatment-induced leukoencephalopathy in primary CNS lymphoma: a clinical and autopsy study. Neurology (2004) 1.15
Primary dural lymphomas: a clinicopathologic study of treatment and outcome in eight patients. Neurology (2006) 1.14
Characteristics and outcomes of elderly patients with primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center experience. Cancer (2010) 1.11
Systemic high-dose intravenous methotrexate for central nervous system metastases. J Neurooncol (2006) 1.11
A phase II trial of single-agent bevacizumab in patients with recurrent anaplastic glioma. Neuro Oncol (2011) 1.09
Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol (2010) 1.08
Recursive partitioning analysis of prognostic factors for glioblastoma patients aged 70 years or older. Cancer (2012) 1.08
Primary central nervous system lymphoma. Neurol Clin (2007) 1.07
The utility of body FDG PET in staging primary central nervous system lymphoma. Neuro Oncol (2008) 1.07
Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study. Oncologist (2010) 1.05
Atypical and anaplastic meningiomas treated with bevacizumab. J Neurooncol (2012) 1.04
Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma. Neuro Oncol (2012) 1.04
Primary CNS lymphoma in children and adolescents: a descriptive analysis from the International Primary CNS Lymphoma Collaborative Group (IPCG). Clin Cancer Res (2011) 1.04
Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma. J Neurosurg (2002) 1.03
A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme. J Neurooncol (2006) 1.02
Central nervous system lymphoma. Hematology Am Soc Hematol Educ Program (2002) 1.02
Current management of metastatic brain disease. Neurotherapeutics (2009) 1.01
Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas. Neuro Oncol (2011) 1.00
Bcl-6 predicts improved prognosis in primary central nervous system lymphoma. Cancer (2008) 0.99
Continuous daily sunitinib for recurrent glioblastoma. J Neurooncol (2012) 0.99
Ischemic stroke and intracranial hemorrhage in glioma patients on antiangiogenic therapy. J Neurooncol (2011) 0.99
Radiotherapy and concomitant temozolomide may improve survival of elderly patients with glioblastoma. J Neurooncol (2012) 0.98
A phase I/II trial of vandetanib for patients with recurrent malignant glioma. Neuro Oncol (2012) 0.97
Longitudinal cognitive follow-up in low grade gliomas. J Neurooncol (2007) 0.97
Cognitive functions in low-grade gliomas: disease and treatment effects. J Neurooncol (2006) 0.96
Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma? J Neurooncol (2002) 0.96
Salvage temozolomide for prior temozolomide responders. Cancer (2005) 0.95
Intracranial hemorrhage in patients treated with bevacizumab and low-molecular weight heparin. Clin Adv Hematol Oncol (2007) 0.95
A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas. Neuro Oncol (2009) 0.94
YKL-40 and MMP-9 as serum markers for patients with primary central nervous system lymphoma. Ann Neurol (2011) 0.94
Initial treatment patterns over time for anaplastic oligodendroglial tumors. Neuro Oncol (2012) 0.92
Late relapse in primary central nervous system lymphoma: clonal persistence. Neuro Oncol (2011) 0.92
Diagnosis and management of primary intraocular lymphoma: an update. Clin Ophthalmol (2007) 0.92
Neurological outcome of long-term glioblastoma survivors. J Neurooncol (2009) 0.92
Imaging of lymphoma of the central nervous system, spine, and orbit. Radiol Clin North Am (2008) 0.89
An update on therapy of primary central nervous system lymphoma. Hematology Am Soc Hematol Educ Program (2006) 0.89
Prognosis and patterns of care in elderly patients with glioma. Cancer (2009) 0.89
CNS Hodgkin lymphoma. Blood (2008) 0.89
Patterns of failure after concurrent bevacizumab and hypofractionated stereotactic radiation therapy for recurrent high-grade glioma. Int J Radiat Oncol Biol Phys (2012) 0.89
Patterns of treatment in older adults with primary central nervous system lymphoma. Cancer (2007) 0.89
Chemotherapy for primary central nervous system lymphoma. Neurosurg Focus (2006) 0.88
Neurooncology clinical trial design for targeted therapies: lessons learned from the North American Brain Tumor Consortium. Neuro Oncol (2008) 0.88
Multicenter phase II study of rituximab and temozolomide in recurrent primary central nervous system lymphoma. Leuk Lymphoma (2012) 0.87
Leukemic and lymphomatous meningitis: incidence, prognosis and treatment. J Neurooncol (2005) 0.87
New frontiers in translational research in neuro-oncology and the blood-brain barrier: report of the tenth annual Blood-Brain Barrier Disruption Consortium Meeting. Clin Cancer Res (2005) 0.87
Primary central nervous system lymphoma: the role of consolidation treatment after a complete response to high-dose methotrexate-based chemotherapy. Cancer (2008) 0.87
Study of radiolabeled indium-111 and yttrium-90 ibritumomab tiuxetan in primary central nervous system lymphoma. Cancer (2007) 0.86
Longitudinal prospective study of matrix metalloproteinase-9 as a serum marker in gliomas. J Neurooncol (2011) 0.85
Age-specific signatures of glioblastoma at the genomic, genetic, and epigenetic levels. PLoS One (2013) 0.85
Bevacizumab in recurrent malignant glioma. Curr Neurol Neurosci Rep (2008) 0.85
A phase II trial of vinorelbine and intensive temozolomide for patients with recurrent or progressive brain metastases. J Neurooncol (2007) 0.85